Latest Content

Imbruvica-Venclexta Combo Superior to Chlorambucil-Obinutuzumab for CLL

June 16th 2021, 9:00pm

By Darlene Dobkowski, MA


The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.

From Segregation to Lifelong Advocacy: A Cancer Survivor Shares His Story

June 16th 2021, 6:00pm

By Jamie Cesanek


In an interview with CURE®, a survivor recounts how his experiences with cancer treatment in the 1960s, when he was treated in a segregated “colored” ward, have led him to a life of advocacy work.

Don’t Let Cancer Keep You From Hiking This Summer

June 16th 2021, 4:00pm

By Felicia Mitchell


“Hiking is a great activity for all of us, including cancer survivors,” writes a breast cancer survivor. “As long as we can put one foot in front of the other, being out on a trail is inspirational and health-affirming.”

Educating Patients About Biomarker Testing

June 16th 2021, 3:21pm


Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.

The Emerging Role of Liquid Biopsies

June 16th 2021, 3:15pm


Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

Bispecific Antibodies Wage a Two-Pronged Attack on Tumors

June 16th 2021, 3:00pm

By Arlene Weintraub


BiTE therapy could lead to better ways to target the immune system, while minimizing the chance of resistance.

Better Prostate Cancer Screening for Younger African American Men May Improve Outcomes

June 16th 2021, 1:00pm

By Jamie Cesanek


Reaching a younger age group of African American men for prostate cancer detection may improve their survival outcomes, says an expert from the University of California San Diego.

Two-Drug Combo Shows Modest Benefit in Biliary Tract Cancer

June 15th 2021, 9:00pm

By Sara Karlovitch


Treatment with the combination of Stivarga and Bavencio was associated with minor anti-tumor activity in patients with advanced, heavily pretreated biliary tract solid tumors.

Novel 4-Drug Combo Significantly Improves Treatment Responses in Group of Patients with Breast Cancer

June 15th 2021, 6:00pm

By Shari Mycek


Treatment with pyrotinib and the chemotherapies trastuzumab, docetaxel and carboplatin significantly improved response rates over the triplet chemotherapy regimen alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

How Does a Patient with Cancer Nominate One Nurse?

June 15th 2021, 4:00pm

By Jane Biehl Ph.D.


A cancer survivor describes how oncology nurses have had a deep impact on her during treatment.

Intralesional Therapies Help Bridge the Gap Between Improved Results and Less Toxicity

June 15th 2021, 3:00pm

By Amy Patural, M.S., M.P.H.


First immunotherapy, intralesional therapy, is making a comeback and producing durable remissions for a subgroup of patients with cancer.

Act Fast: Side Effects of Immunotherapy

June 15th 2021, 1:00pm

By Antonia DePace


Experts urge patients to stop playing the wait-and-see game: There’s no ‘playbook’ for immunotherapy-related toxicities, and side effects can be managed if caught early.

CNN Anchor Christiane Amanpour Receiving Treatment for Ovarian Cancer

June 14th 2021, 9:03pm

By Darlene Dobkowski, MA


CNN’s chief international anchor announced her ovarian cancer diagnosis live on-air today, which she wants everyone to use as a call to arms for all people to undergo cancer screening.

Standing Firm Against the Financial Burden of Cancer

June 14th 2021, 9:00pm

By Antonia DePace


To avoid the financial burden of costly therapies, patients with cancer receiving immunotherapy treatments should talk with their health care team and not settle for no as an answer from their health insurance provider, according to an expert.

Yescarta Associated With Better Outcomes Than Other Available Treatments for Relapsed/Refractory Follicular Lymphoma

June 14th 2021, 6:00pm

By Colleen Moretti


These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.